1. Ries L, Kosary C, Hankley B.SEER Cancer Statistics Review, 1973- 1994. Bethesda, Md: National Institutes of Health; 1997: 97-2789.
2.
2. Lee C, Katz J, Fearn P, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2003; 7: 135-140.
3.
3. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. JUrol. 1969; 101: 297-301.
4.
4. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000; 75: 1236-1242.
5.
5. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002; 59: 816-820.
6.
6. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 1655-1659.
7.
7. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998; 338: 1265-1271.
8.
8. Bloom HJ. Proceedings: hormone-induced and spontaneous regression of metastatic renal cancer. Cancer. 1973; 32: 1066-1071.
10. MacManus MP, Harte RJ, Stranex, S. Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour. Ir J Med Sci. 1994; 163: 461-463.
11.
11. Moyad MA. Review of potential risk factors for kidney (renal cell) cancer. Semin Urol Oncol. 2001; 19: 280-293.
12.
12. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 992-993.
13.
13. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. JUrol. 1999; 162: 1277-1281.
14.
14. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-663.
15.
15. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am. 2003; 30: 467-480.
16.
16. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002; 20: 1368-1374.
17.
17. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001; 19: 1649-1657.
18.
18. Zisman A, Pantuck, AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559-4566.
19.
19. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial. Lancet. 2001; 358: 966-970.
20.
20. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995; 22: 42-60.
21.
21. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol. 1983; 10: 422-430.
22.
22. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999; 17: 2859-2867.
23.
23. Bordin V, Giani L, Meregalli S, et al. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int. 2000; 64: 3-8.
24.
24. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6(suppl 1): S55-S57.
25.
25. Lissoni P, Bordin V, Vaghi M, et al. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Anticancer Res. 2002; 22: 1061-1064.
26.
26. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 2001; 345: 1711-1712.
27.
27. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999; 353: 14-17.
28.
28. Fossa S, Jones M, Johnson P, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol. 1995; 76: 286-290.
29.
29. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992; 3: 475-480.
30.
30. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol. 1999; 17: 2039-2043.
31.
31. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998; 338: 1272-1278.
32.
32. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 1993; 29A(suppl 5): S6-S8.
33.
33. Allen MJ, Vaughan M, Webb A, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer. 2000; 83: 980-985.
34.
34. Savage P, Costelna D, Moore J, Gore ME. A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer. Eur J Cancer. 1997; 33: 1149-1151.
